Historical Group Debriefing Following Combat

1993 ◽  
Author(s):  
Arieh Shalev
Keyword(s):  
Historical Group

scholarly journals Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19

Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 436
Author(s):  
Monika Maria Biernat ◽  
Anna Kolasińska ◽  
Jacek Kwiatkowski ◽  
Donata Urbaniak-Kujda ◽  
Paweł Biernat ◽  
...  
Keyword(s):  
Overall Survival ◽  
High Risk ◽  
Hematological Malignancies ◽  
Treated Group ◽  
Viral Clearance ◽  
Early Administration ◽  
Improved Outcomes ◽  
Historical Group ◽  
High Risk Populations ◽  
Diagnosis Of Infection

The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23 patients with hematological malignancies and COVID-19 who had received plasma 48–72 h after the diagnosis of infection and compared it with a historical group of 22 patients who received other therapy. Overall survival in those who received convalescent plasma was significantly higher than in the historical group (p = 0.03460). The plasma–treated group also showed a significantly milder course of infection (p = 0.03807), characterized by less severe symptoms and faster recovery (p = 0.00001). In conclusion, we have demonstrated that convalescent plasma is an effective treatment and its early administration leads to clinical improvement, increased viral clearance and longer overall survival in patients with hematological malignancies and COVID-19. To our knowledge, this is the first report to analyze the efficacy of convalescent plasma in a cohort of patients with hematological malignancies.

scholarly journals Diversity of Segetal Flora in Salix viminalis L. Crops Established on Former Arable and Fallow Lands in Central Poland

Agriculture ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 25
Author(s):  
Maria Janicka ◽  
Aneta Kutkowska ◽  
Jakub Paderewski
Keyword(s):  
Native Species ◽  
Life Form ◽  
Arable Land ◽  
Salix Viminalis ◽  
Central Poland ◽  
Plant Groups ◽  
Fallow Lands ◽  
Historical Group ◽  
Phytosociological Relevés ◽  
Segetal Flora

The flora of willow (Salix viminalis L.) plantations consists of various plant groups, including plants related to arable land, called segetal plants. Knowledge of this flora is important for maintaining biodiversity in agroecosystems. The aim of the study was to assess the segetal flora of the willow plantations in central Poland, depending on the land use before the establishment of the plantations (arable land or fallow) and the age of the plantations. Moreover, the aim was also to check for the presence of invasive, medicinal, poisonous and melliferous species. The vegetation accompanying willow was identified based on an analysis of 60 phytosociological relevés performed using the Braun-Blanquet method. For each species, the following parameters were determined: the phytosociological class; family; geographical and historical group; apophyte origin; biological stability; life-form; and status as an invasive, medicinal (herbs), poisonous or melliferous species. The results were statistically processed. Segetal species accounted for 38% of the flora accompanying willow. The plantations on former arable land were richer in segetal species than those on fallow. Mostly, short-lived and native species dominated. In line with the age of the plantations, the number of segetal species decreased. The share of apophytes increased, and anthropophytes decreased. Furthermore, many valuable plants were found among the flora accompanying willow.

scholarly journals Historical Group Debriefing after Combat Exposure

1998 ◽  
Vol 163 (7) ◽  
pp. 494-498 ◽  
Author(s):  
Arieh Y. Shalev ◽  
Tuvia Peri ◽  
Yael Rogel-Fuchs ◽  
Robert J. Ursano ◽  
David Marlowe
Keyword(s):  
Combat Exposure ◽  
Historical Group

Renal Transplantation in Patients on Peritoneal Dialysis

1985 ◽  
Vol 5 (3) ◽  
pp. 157-160 ◽  
Author(s):  
Neal R. Glass ◽  
Douglas T. Miller ◽  
Hans W. Sollinger ◽  
Stephen W. Zimmerman ◽  
David Simpson ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Renal Transplantation ◽  
Peritoneal Dialysis Catheter ◽  
Dialysis Catheter ◽  
Dialysis Patients ◽  
Oral Steroids ◽  
Historical Group ◽  
Group 3 ◽  
Group 2 ◽  
High Doses

The authors reviewed the course of 56 peritoneal dialysis patients after renal transplantation to determine the influence of this mode of dialysis on the results of transplantation. Three subgroups were analyzed separately because of marked differences in results. Group 1 was a historical group of 13 diabetic and two nondiabetic recipients of cadaveric grafts transplanted before 1982 who received standard immunosuppression with steroids and azathioprine only, and antirejection therapy with steroids and/or antithymocytic globulin (ATG). In this group results were poor: only 100/o of grafts and 670/o of patients survived two years or more. Group 2, the current group of cadaveric recipients, consists of 11 diabetic and nine nondiabetic patients transplanted since 1982; these patients received standard immunosuppression with low-dose steroids, azathioprine, and a two-week course of prophylactic ATG beginning within one day of transplantation; rejection was treated with high doses of oral steroids. In this second group, results were good: 630/o of the grafts are functioning and 100% of patients have survived for up to two years. Group 3, consisting of 21 recipients of living donor kidneys, had excellent results with 1000/o graft and patient survival up to five years. Rejection (N = 11), death (N = 5) and renovascular problems (N = 3) caused the 19 graft losses. In most patients the dialysis catheters were removed three weeks to three months after transplantation when renal function was stable. There were two minor complications and no infections related to the catheters. We conclude that: a) excellent transplant results can be achieved in peritoneal dialysis patients, most of whom are diabetic and receive cadaveric grafts, b) the peritoneal dialysis catheter is not a significant source of peritransplant morbidity and therefore c) peritoneal dialysis is appropriate for patients awaiting renal transplantation and should not bias against their selection for transplantation. The published literature on kidney transplantation in patients on peritoneal dialysis is sparse, suggesting that it is not, and perhaps should not be common practice to transplant these patients. This study and review of the literature was undertaken 1) to characterize peritoneal dialysis patients undergoing renal transplantation at our center, 2) to determine the results of transplantation in this group, 3) to evaluate the risk to these patients from the peritoneal dialysis catheter itself and 4) to compare our experience with the literature concerning renal transplantation of peritoneal dialysis patients.

scholarly journals Topical Nanofat Biocrème Improves Aesthetic Outcomes of Nonablative Fractionated Laser Treatment: A Preliminary Report

2019 ◽  
Vol 40 (8) ◽  
pp. 892-899 ◽  
Author(s):  
Steven R Cohen ◽  
Ashley K Goodacre ◽  
Hayley Womack ◽  
Flore Delaunay ◽  
Danielle Wood ◽  
...  
Keyword(s):  
Platelet Rich Plasma ◽  
Nasolabial Fold ◽  
Laser Resurfacing ◽  
Delivery Vector ◽  
Before And After ◽  
Skin Erythema ◽  
Historical Group ◽  
Skin Biopsies ◽  
Nasolabial Folds ◽  
Histologic Changes

Abstract Background Improvements in skin erythema and elasticity have been observed with topical application of platelet-rich plasma after fractional laser (FXD) treatment. Injections of nanofat via small needles into the dermis improves tissue thickness, discoloration and wrinkle depth. Objectives The aim of this study was to evaluate improvements in skin following a nonablative FXD treatment combined with the application of a novel topical nanofat biocrème, called neo-U. Methods Fifty patients were treated with a nonablative FXD followed by application of a topical nanofat biocrème. Harvested fat was processed into nanofat, which was compounded with a transdermal liposomal delivery vector to produce a topical biocrème. In 2 patients, postauricular skin punch biopsies were performed before and after treatment and examined for histologic changes. Photographs of a historical group treated with only the FXD were compared with photographs of patients treated with a combination of topical nanofat biocrème and FXD. Skin types were evaluated for improvements in nasolabial folds, wrinkles, and skin texture. Results Findings from postauricular skin biopsies show the skin exposed to FXD with nanofat biocrème had more elastin fibers and a slight increase in the thickness of the epidermis. Patients treated with FXD plus nanofat biocrème had a statistically significant improvement in the degree of wrinkles, nasolabial fold depth, and texture compared with historical controls. Conclusions Transdermal delivery of nanofat topical biocrème applied after FXD treatment can serve as a delivery system to improve fine lines, nasolabial fold depth, and overall texture of the tissue to a greater degree than laser resurfacing alone.

R.101 and Other Airships—The Process of Development

1962 ◽  
Vol 66 (620) ◽  
pp. 489-498
Author(s):  
T. R. Cave-Browne-Cave
Keyword(s):  
General Consideration ◽  
Technical Detail ◽  
Personal Problems ◽  
Historical Group

In addressing the Historical Group it is desirable to let technical detail fall into the background so that the more general consideration of personal problems, policy and organisation can be clearly examined.Technical detail changes so much more with time than do the human and administrative considerations, that the greatest value for history comes perhaps from the study of the latter.

Decitabine Low-Dose Schedule (100 mg/m2/course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1437-1437 ◽  
Author(s):  
Hagop M. Kantarjian ◽  
Farhad Ravandi ◽  
Susan O’Brien ◽  
Francis Giles ◽  
Stefan Faderl ◽  
...  
Keyword(s):  
Myeloid Leukemia ◽  
Low Dose ◽  
Optimal Dose ◽  
Dose Schedule ◽  
Overall Response ◽  
Transfusion Independence ◽  
Historical Group ◽  
Secondary Mds ◽  
To Receive

Abstract Decitabine, a hypomethylating agent, has shown activity in MDS, acute myeloid leukemia (AML), and chronic myeloid leukemia. In this study, we investigated optimizing the dose schedule. Patients with IPSS intermediate 1–2 and high risk were randomized to one of 3 schedules of decitabine: 1) 20 mg/m2 IV over 1 hour daily x 5; 2) 10 mg/m2 IV over 1 hour daily x 10; or 3) 10 mg/m2 subcutaneously (SQ) BID x 5. A total of 90 patients are to be treated. Randomization is equal until the 45th patient after which a Bayesian (play by the winner) randomization is implemented based on CR rates. Courses were given every 28 days regardless of counts, as long as counts recovered to pretreatment + evidence of disease on repeat marrow + no significant myelosuppression complications. Delays to allow for recovery of counts were permitted every 3 courses, or in the presence of myelosuppression without disease or severe myelosuppression-related complications. Patients were allowed to receive erythropoietin 40,000 units weekly for anemia, or GCSF if needed during febrile neutropenia. Response criteria for CR and PR were as for AML (PR requiring also decrease blasts by >50%). Clinical benefit (CB) referred to one or more of the following: platelets increase by 50% and above 30 x 109/L, or granulocytes increase by 100% and to above 109/L, or hemoglobin increase by 2 g/dl or transfusion independence, or splenomegaly decrease by 50% or more, or monocytes decrease by 50% or more (pretreatment >5 x 109/L). 43 patients have been treated; median age 63 years (range 39 to 90); 60 (26%) were ≥ 60 years old. IPSS risk: intermediate 1 –13 (30%); intermediate 2–13 (30%); high-(23%); CMML-7(16%). Cytogenetic abnormalities were present in 56%; secondary MDS in 23%; marrow blasts ≥ 10% in 30%. 22 patients had prior erythropoietin; 9 had prior GCSF; 12 had other prior therapies (thalidomide 6, azacytidine 2, other 4). Presently, 36 patients have received at least 1 course of therapy. Results were: 10 CR (28%); 3 PR (9%); 18 CB (50%); overall response 31/36=86%. 22(51%) patients required hospitalizations for fever and neutropenia. Median courses to CR was 1 (range 1 to 3); 5 patients (50%) needed 2 or more courses to achieve CR. With a median follow-up of 4 months, 5 have evolved into AML; 4 have died (2 AML; 2 MDS); 35 patients continue on decitabine therapy. Compared with a historical group of 54 patients with MDS who received intensive chemotherapy (2000–2003) and matched for age, cytogenetics and IPSS/FAB, the CR rate was lower with decitabine (28% vs 47%), but the overall response rate was favorable; the 8-week mortality was also lower with decitabine (7% vs 26%); and estimated survival favorable (6-month rates 80% vs 67%). CR rates by schedule were: 5 days IV 6/15 (40%); 5 days SQ 2/11 (18%); 10 day IV 2/10 (20%). There was more myelosuppression with the 10 day IV schedule. We conclude that 1) decitabine at this low-dose schedule has major anti- MDS activity in the setting of poorer risk MDS; 2) the optimal dose schedule is being defined; 3) side effects are acceptable; 4) timely and repeated courses of decitabine therapy is required for optimal response results.

Long-Term Follow-Up Confirms the Benefit of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) as Front Line Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 565-565 ◽  
Author(s):  
Yuan-Fang Liu ◽  
Yong-Mei Zhu ◽  
Zhan-Zhong Shi ◽  
Jun-Min Li ◽  
Li Wang ◽  
...  
Keyword(s):  
Remission Induction ◽  
Newly Diagnosed ◽  
Front Line ◽  
Current Group ◽  
Historical Cohort ◽  
Term Survival ◽  
Long Term Survival ◽  
Historical Group

Abstract PURPOSE: To further confirm the benifit of front-line use of all-trans retinoic acid (ATRA) combined with arsenic trioxide (As2O3) in patients with newly diagnosed acute promyelocytic leukemia (APL), we observed the long-term survival of the current group (median follow-up: 48 months) and compared it with our historical control. PATIENTS AND METHODS: There were two groups of patients with newly diagnosed APL enrolled in this analysis. The current cohort of patients includes 60 patients since April 2001. The historical cohort of patients included 56 patients from May 1998 to March 2001. No statistically significant differences were found between these two groups in terms of clinical characteristics including sex and age distribution or hematological data before treatment. For the current cohort of patients, all patients received 25mg/m2 ATRA orally and 0.16mg/kg As2O3 intravenously per day till CR. Once CR achieved, they were given 3 courses of consolidation chemotherapy and then 5 cycles of sequential treatment of ATRA, As2O3 and 6-MP/MTX. For the historical group, ATRA was given either 25mg/m2 daily till CR, chemotherapy was added in case of leukocytosis. The post-remission therapy consists of chemotherapy with or without ATRA. Quantitative real-time reverse transcription-polymerase chain reaction (RQ-RT-PCR) measurements of PML-RARa mRNA were retrospectively assessed before treatment, after CR, after consolidation, after maintenance and during follow-up period. The efficacy of these two protocol in terms of remission induction, molecular response and long-term survival were compared with our historical control. RESULT: In the current group, 56 (93.3%) patients achieved CR, and the median time to CR was 27 days. Compared with the historical group, the combined therapy induced an early hematological response. Till the last follow-up at April 2006, two patients underwent extramedullary relapse, one of them also relapsed in marrow thereafter, one patient died from CNS leukemia, and all the other patients were alive and remained in hematological remission. With a median follow-up of 48 months (25 to 60 months), the 4-year OS and EFS was estimated 98.1%±1.8% and 94.2%±3.3%. For the historical group, after a median follow-up of 56 months (12 to 79 months), the 4-year OS and EFS was estimated 83.4%±5.4% (P=0.012) and 45.6%±7.6% (P<0.00001). For the current group, PML-RARa normalized dose was more significantly decreased after remission induction and after consolidation as compared with the historical cohort. In the last follow-up, all of the available event-free patients of the current group remain in molecular remission (PML-RARa DoseN undetectable). CONCLUSION: These 4-year data of follow-up demonstated a benefit of front-line combination of ATRA and As2O3 regarding long-term survival (OS or EFS) of patients with newly diagnosed APL. With prolonged follow-up, we might be able to find a better chance of curing the disease.

Sign in / Sign up

Export Citation Format

Share Document